0.8056
3.98%
-0.0334
After Hours:
.8149
0.0093
+1.15%
Ginkgo Bioworks Holdings Inc stock is currently priced at $0.8056, with a 24-hour trading volume of 31.35M.
It has seen a -3.98% decreased in the last 24 hours and a -7.57% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8338 pivot point. If it approaches the $0.7792 support level, significant changes may occur.
Previous Close:
$0.839
Open:
$0.84
24h Volume:
31.35M
Market Cap:
$1.78B
Revenue:
$251.46M
Net Income/Loss:
$-892.87M
P/E Ratio:
-1.1346
EPS:
-0.71
Net Cash Flow:
$-336.30M
1W Performance:
+5.87%
1M Performance:
-7.57%
6M Performance:
-47.00%
1Y Performance:
-36.57%
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
877 422 5362
Address
27 Drydock Avenue, 8th Floor, Boston
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Nov-29-22 | Initiated | Berenberg | Buy |
Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-02-22 | Resumed | Cowen | Outperform |
Feb-23-22 | Initiated | Goldman | Neutral |
Feb-01-22 | Initiated | BofA Securities | Neutral |
Jan-28-22 | Initiated | BofA Securities | Buy |
Jan-07-22 | Initiated | BTIG Research | Buy |
Nov-29-21 | Initiated | Jefferies | Buy |
Oct-13-21 | Initiated | Raymond James | Outperform |
Oct-12-21 | Initiated | William Blair | Outperform |
Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Is Ginkgo Bioworks Holdings Stock a Buy?
The Motley Fool
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives $2.20 Average Price Target from Analysts - Defense World
Defense World
Ginkgo Bioworks (NYSE:DNA) Downgraded by BTIG Research to “Sell” - Defense World
Defense World
Ginkgo Bioworks (NYSE:DNA) Given New $1.00 Price Target at Morgan Stanley - Defense World
Defense World
July 19th Options Now Available For Ginkgo Bioworks Holdings - Nasdaq
Nasdaq
Goldman Sachs Downgrades Ginkgo Bioworks Holdings Inc - (DNA) - MSN
MSN
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Ginkgo Bioworks Holdings Inc (DNA) Revenue 2024
DNA reported a revenue (TTM) of $251.46 million for the quarter ending December 31, 2023, a -47.36% decline year-over-year.
Ginkgo Bioworks Holdings Inc (DNA) Net Income 2024
DNA net income (TTM) was -$892.87 million for the quarter ending December 31, 2023, a +57.58% increase year-over-year.
Ginkgo Bioworks Holdings Inc (DNA) Cash Flow 2024
DNA recorded a free cash flow (TTM) of -$336.30 million for the quarter ending December 31, 2023, a -10.45% decrease year-over-year.
Ginkgo Bioworks Holdings Inc (DNA) Earnings per Share 2024
DNA earnings per share (TTM) was -$0.47 for the quarter ending December 31, 2023, a +63.57% growth year-over-year.
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to advance treatments for orphan and rare diseases. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Cap:
|
Volume (24h):